Abstract

This grant application requests funding to continue support for investigators at the Arizona Cancer Center to improve cancer treatment for humans by participation in the Southwest Oncology Group.
Specific aims i nclude: 1. To develop scientific leads using the laboratories and clinics of the Arizona Cancer Center (University of Arizona) worthy of testing in a national cooperative group (Southwest Oncology Group). 2. To incorporate these pilot experiences into large confirmatory or randomized multi-institution trials. 3. To increase participation in Southwest Oncology Group trials by entering a larger number of patients on studies. 4. To continue and expand our already large commitment to scientific leadership of the Southwest Oncology Group. 5. To make available state-of-the-art treatment to a large proportion of patients throughout the State of Arizona by increasing the number of community clinical research satellites interested in participating in Southwest Oncology Group studies.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA013612-15
Application #
3556193
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1978-01-01
Project End
1992-12-31
Budget Start
1988-01-01
Budget End
1988-12-31
Support Year
15
Fiscal Year
1988
Total Cost
Indirect Cost

  Institution

Name
University of Arizona
Department
Type
Schools of Medicine
DUNS #
City
Tucson
State
AZ
Country
United States
Zip Code
85722

  Publications

Lemieux, Julie; Brundage, Michael D; Parulekar, Wendy R et al. (2018) Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years. J Clin Oncol 36:563-571
Persky, Daniel O; Li, Hongli; Rimsza, Lisa M et al. (2018) A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. Am J Hematol 93:486-493
Rimsza, Lisa M; Li, Hongli; Braziel, Rita M et al. (2018) Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort. Haematologica 103:e151-e153
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Danilov, Alexey V; Li, Hongli; Press, Oliver W et al. (2017) Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial. Leuk Lymphoma 58:461-465
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40
Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952
Durie, Brian G M; Hoering, Antje; Abidi, Muneer H et al. (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389:519-527
Goss, Paul E; Ingle, James N; Pritchard, Kathleen I et al. (2016) Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. N Engl J Med 375:209-19
Ravandi, Farhad; Othus, Megan; O'Brien, Susan M et al. (2016) US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL. Blood Adv 1:250-259

Showing the most recent 10 out of 211 publications